BACKGROUND: For bladder cancer (BCa) patients undergoing bladder-sparing treatments, molecular markers may aid in accurately predicting progression to muscle invasion and recurrence. Hyaluronic acid (HA) is a glycosaminoglycan that promotes tumor metastasis. Hyaluronoglucosaminidase 1 (HYAL-1)-type hyaluronidase (HAase) promotes tumor growth, invasion, and angiogenesis. Urinary HA and HAase levels are diagnostic markers for BCa. OBJECTIVE: We evaluated whether HA and HYAL-1 can predict progression to muscle invasion and recurrence among patients with non-muscle-invasive BCa. DESIGN, SETTING, AND PARTICIPANTS: : Based on tissue availability, tissue microarrays were prepared from a cohort of 178 BCa specimens (144 non-muscle invasive, 34 muscle invasive). Follow-up information was available on 111 patients with non-muscle-invasive BCa (mean follow-up: 69.5 mo); 58 patients recurred and 25 progressed to muscle invasion (mean time to progress: 22.3 mo). MEASUREMENTS: HA and HYAL-1 expression was evaluated by immunohistochemistry and graded for intensity and area of staining. Association of HA and HYAL-1 staining with BCa recurrence and muscle invasion was evaluated by univariate and multivariate models. RESULTS AND LIMITATIONS: HA and HYAL-1 expression correlated with tumor grade, stage, and multifocality (p<0.05). In non-muscle-invasive BCa specimens, HYAL-1 staining was higher (234.3+/-52.2; 200.6+/-61.4) if patients experienced progression to muscle invasion or recurrence when compared with no progression or recurrence (164.1+/-48.2; 172.1+/-57; p<0.001). HA staining correlated with muscle invasion (p<0.001). In univariate analysis, age (p=0.014), multifocality (p=0.023), and HYAL-1 staining (p<0.001) correlated with muscle invasion, whereas only HYAL-1 correlated with recurrence (p=0.013). In multivariate analysis, HYAL-1 significantly associated with muscle invasion (p<0.001; 76.8% accuracy) and recurrence (p=0.01; 67.8% accuracy). CONCLUSIONS: HYAL-1 is a potential prognostic marker for predicting progression to muscle invasion and recurrence.
BACKGROUND: For bladder cancer (BCa) patients undergoing bladder-sparing treatments, molecular markers may aid in accurately predicting progression to muscle invasion and recurrence. Hyaluronic acid (HA) is a glycosaminoglycan that promotes tumor metastasis. Hyaluronoglucosaminidase 1 (HYAL-1)-type hyaluronidase (HAase) promotes tumor growth, invasion, and angiogenesis. Urinary HA and HAase levels are diagnostic markers for BCa. OBJECTIVE: We evaluated whether HA and HYAL-1 can predict progression to muscle invasion and recurrence among patients with non-muscle-invasive BCa. DESIGN, SETTING, AND PARTICIPANTS: : Based on tissue availability, tissue microarrays were prepared from a cohort of 178 BCa specimens (144 non-muscle invasive, 34 muscle invasive). Follow-up information was available on 111 patients with non-muscle-invasive BCa (mean follow-up: 69.5 mo); 58 patients recurred and 25 progressed to muscle invasion (mean time to progress: 22.3 mo). MEASUREMENTS: HA and HYAL-1 expression was evaluated by immunohistochemistry and graded for intensity and area of staining. Association of HA and HYAL-1 staining with BCa recurrence and muscle invasion was evaluated by univariate and multivariate models. RESULTS AND LIMITATIONS: HA and HYAL-1 expression correlated with tumor grade, stage, and multifocality (p<0.05). In non-muscle-invasive BCa specimens, HYAL-1 staining was higher (234.3+/-52.2; 200.6+/-61.4) if patients experienced progression to muscle invasion or recurrence when compared with no progression or recurrence (164.1+/-48.2; 172.1+/-57; p<0.001). HA staining correlated with muscle invasion (p<0.001). In univariate analysis, age (p=0.014), multifocality (p=0.023), and HYAL-1 staining (p<0.001) correlated with muscle invasion, whereas only HYAL-1 correlated with recurrence (p=0.013). In multivariate analysis, HYAL-1 significantly associated with muscle invasion (p<0.001; 76.8% accuracy) and recurrence (p=0.01; 67.8% accuracy). CONCLUSIONS:HYAL-1 is a potential prognostic marker for predicting progression to muscle invasion and recurrence.
Authors: V B Lokeshwar; D Rubinowicz; G L Schroeder; E Forgacs; J D Minna; N L Block; M Nadji; B L Lokeshwar Journal: J Biol Chem Date: 2001-01-19 Impact factor: 5.157
Authors: S H Hautmann; V B Lokeshwar; G L Schroeder; F Civantos; R C Duncan; R Gnann; M G Friedrich; M S Soloway Journal: J Urol Date: 2001-06 Impact factor: 7.450
Authors: Essi L J Hiltunen; Maarit Anttila; Anne Kultti; Kirsi Ropponen; Jorma Penttinen; Merja Yliskoski; Arja T Kuronen; Matti Juhola; Raija Tammi; Markku Tammi; Veli-Matti Kosma Journal: Cancer Res Date: 2002-11-15 Impact factor: 12.701
Authors: P Auvinen; R Tammi; J Parkkinen; M Tammi; U Agren; R Johansson; P Hirvikoski; M Eskelinen; V M Kosma Journal: Am J Pathol Date: 2000-02 Impact factor: 4.307
Authors: Vinata B Lokeshwar; Grethchen L Schroeder; Marie G Selzer; Stefan H Hautmann; J Timothy Posey; Robert C Duncan; Roger Watson; Lyndon Rose; Steven Markowitz; Mark S Soloway Journal: Cancer Date: 2002-07-01 Impact factor: 6.860
Authors: Andrew Chi; Samir P Shirodkar; Diogo O Escudero; Obi O Ekwenna; Travis J Yates; Rajinikanth Ayyathurai; Michael Garcia-Roig; Jeffrey C Gahan; Murugesan Manoharan; Vincent G Bird; Vinata B Lokeshwar Journal: Cancer Date: 2011-09-01 Impact factor: 6.860
Authors: Maria Frantzi; Agnieszka Latosinska; Leif Flühe; Marie C Hupe; Elena Critselis; Mario W Kramer; Axel S Merseburger; Harald Mischak; Antonia Vlahou Journal: Nat Rev Urol Date: 2015-05-26 Impact factor: 14.432
Authors: Vinata B Lokeshwar; Daley S Morera; Sarrah L Hasanali; Travis J Yates; Marie C Hupe; Judith Knapp; Soum D Lokeshwar; Jiaojiao Wang; Martin J P Hennig; Rohitha Baskar; Diogo O Escudero; Ronny R Racine; Neetika Dhir; Andre R Jordan; Kelly Hoye; Ijeoma Azih; Murugesan Manoharan; Zachary Klaassen; Sravan Kavuri; Luis E Lopez; Santu Ghosh; Bal L Lokeshwar Journal: Clin Cancer Res Date: 2020-02-24 Impact factor: 12.531
Authors: Helen Bouga; Isidoros Tsouros; Dimitrios Bounias; Dora Kyriakopoulou; Michael S Stavropoulos; Nikoletta Papageorgakopoulou; Dimitrios A Theocharis; Demitrios H Vynios Journal: BMC Cancer Date: 2010-09-17 Impact factor: 4.430
Authors: Timo K Nykopp; Kirsi Rilla; Markku I Tammi; Raija H Tammi; Reijo Sironen; Kirsi Hämäläinen; Veli-Matti Kosma; Seppo Heinonen; Maarit Anttila Journal: BMC Cancer Date: 2010-09-27 Impact factor: 4.430
Authors: Kevin T Dicker; Lisa A Gurski; Swati Pradhan-Bhatt; Robert L Witt; Mary C Farach-Carson; Xinqiao Jia Journal: Acta Biomater Date: 2013-12-18 Impact factor: 8.947
Authors: Frederikke Lihme Egerod; Annette Bartels; Niels Fristrup; Michael Borre; Torben F Ørntoft; Martin B Oleksiewicz; Nils Brünner; Lars Dyrskjøt Journal: BMC Cancer Date: 2009-10-30 Impact factor: 4.430